Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Background: Glatiramer acetate (GA) treatment suppresses disease activity in multiple sclerosis (MS). The immunological response to treatment may differ in patients who are stable on GA therapy and patients with breakthrough disease activity, but the results of previous studies are inconsistent. Objectives: We studied the immunological response to GA and its relationship with disease activity. Methods: Anti-GA antibodies in plasma and the expression of genes encoding cytokines and T-cell-polarizing transcription factors in blood cells were analysed by flow cytometric bead array and polymerase chain reaction (PCR) analysis in 39 untreated and 29 GA-treated relapsing-remitting MS patients. Definition of breakthrough disease was based on the occurrence of relapses, disability progression, or gadolinium (Gd)-enhanced MRI. Results: The expression of T helper type 1 (Th1) and Th17 cytokines and transcription factors was reduced during long-term treatment, but there was no relationship between the expression of cytokines and transcription factors and anti-GA antibodies. High expression of mRNA encoding GATA3 and lymphotoxin-β (LT-β) was associated with low disease activity in Gd-enhanced MRI studies. None of the variables studied were associated with clinical disease activity. GA treatment resulted in the development of IgG and IgG4 anti-GA antibodies during the first months of treatment, persisting during long-term treatment. Conclusions: The observed relationship between the expression of mRNA encoding GATA3 and LT-β expression and MRI disease activity deserves further analysis in future studies. The development of anti-GA antibodies was observed in all patients treated with GA, but this was not related with measures of cellular immunity, clinical or MRI disease activity.
Original languageEnglish
JournalMultiple Sclerosis
ISSN1352-4585
DOIs
Publication statusPublished - 2011

ID: 33166248